Skip Navigation LinksPerformance-Trends-for-US-CA-Objectives

Top Menu

TUBERCULOSIS CONTROL BRANCH

California Tuberculosis Performance Trends with California Targets and United States Performance​

Most Recent Five Years of Data Available, 2019-2023, 2020-2024, and 2021-2025

​Strategy 1: Diagnosis and Treatment of Persons with TB Disease

Objective​​

​2019

​2020

​2021

​2022

​2023

​2024

​2025

​CA Target*

​​US Average**

​1.1a TB Case Rate (per 100,000 population)​​

​—

​—

​4.5

​4.7

​5.4

​5.4

​5.5

​4.7

​​3.0

​1.1b US-Born Case Rate​​

​—

—

​1.1

​1.1

​1.2

​1.2

​1.3

​1.0

​0.8

​1.1c Non US-Born Case Rate

​—

​—

​13.6

​14.7

​16.5

​16

16​

​15.1

15.3

​1.1d African American Case Rate

​​—

​—

​1.7

​2.1

​2.4

​1.9

​1.6

​1.6*

​​1.9**

​1.1e Pediatric Case Rate

​​—​

​—

​1.1

​1.2

​1.2

​1.2

​1.5

​0.9

​1.2

​1.1f Asian Case Rate​​

​​—

—​

​14.7

​15.3

16.7​

​16.2

​16

​15.9

​NA

​1.1g Hispanic/Latinx Case Rate

​​—

​—

​4.5

​4.8

​5.4

​5.7

​5.6

4.5

​NA

​1.1h White Case Rate

​​—

​—

​0.7

​0.7

​1.0

​0.8

0.9​

​0.8

​NA

​1.2 Known HIV Status (%)

​​—

​—

​90

​92

​93

​90

89​

​92

​90​

​1.3 Laboratory Turnaround Time — Culture (%)​

​—

​—​

​53

​48

​47

​39

​41

​52

​47

​1.4 Laboratory Turnaround Time — NAAT (%)

​​—​

​—

​90

​85

​81

​83

​87

​89

​82**

​1.5 Drug Susceptibility Result (%)

​​—

​​—

​96

​98

​97

​97

​94

​96

​89**

​1.6 Sputum Culture Reported (%)

​​—

​​—

​95

​96

​94

​94

​94

​93*

​92**

​1.7 Recommended Initial Therapy (%)

​​—

​​—

​90

​91

​91

​91

​90

​94

​89**

​​1.8 Treatment Initiation (%)

​​—​​

​​—​

​85

​84

​88

​87

​88

​91

​88**

​1.9 Sputum Culture Conversion (%)​

​74

​74

​71

​70

​71

​—

​​—

​76

​​68

​1.10 Completion of Treatment (%)

​​89

90​

86​

86

85

​​—​

​​—

91​

84**

​1.11a Nucleic Acid Amplification Test Used - Smear-Positive TB (%)

​​—

​​—

78​

71

76

78

​85

73*

NA​

​1.11b Nucleic Acid Amplification Test Used - Smear-Negative TB (%)

​​—

—

43​

46​

52

57​

65​

47*

​NA

​1.12 Self-Administered Therapy (%)

​2.3

​2.1

​1.4

4.4

5.9

​—

—​

1.7​

​NA

​1.13 Deaths With TB (%)

​11.5

​13.4

​12.4

​14.0

13

—​

—​​

6.0

​NA​

Strategy 2A: Contact Investigation of Infectious TB Cases

​Objective
​2019
​2020
​2021
​2022
​2023
​2024
​2025
​CA Target*
​US Average**
​2A.1 Contact Elicitation (%)
​—​
​91
​92
​88
​89
89
—
98
88**
​2A.2 Contact Examination (%)
​—
​82
​82
​78
​77
76
​—
92
74**
​2A.3 Contact LTBI Treatment Initiation (%)
​—
​75
​78
​71
​68
68
​—
77
73
​2A.4 Contact LTBI Treatment Completion (%)
​—
​74
​74
​73
​68
65​
—​85
79

​​Strategy 2B: Examination and Treatment of Immigrants and Refugees with Class B1 Notification

​Objective

​2019
​2020
​2021
​2022
​2023
​2024
​2025

​CA Target*
​US Average**
2B.1 Immigrant/Refugee Evaluation Initiation within 30 Days (%)​​—
—
​25
​18
​19
20
18​30
32
​2B.2 Immigrant/Refugee Evaluation Completion within 120 Days (%)
​—
—​
​38
​28
​29
33
25​33
37
​2B.3 Immigrant/Refugee Evaluation Complete (%)
​—
​—​
​61
​​57
​56
​49
39​​54
​NA
2B.4 Immigra​​nt/Refugee LTBI Treatment Initiation (%)
​—
​71
​62
​65
​59
54
—​78
60
​2B.5 Immigrant/Refugee LTBI Treatment Completion (%)​​
​—
​85
​68
​79
​71
​48
—​​​74
​​65
​2B.6 Data Reporting —​ EDN (%)​
​—
​7​0
​73
​71
​68
​68
​—
​87
​​71

Strategy 4: Epidemiologic Surveillance and Response

​Objective
​​2019
​2020​
​2021
​2022
​2023
​2024
​2025
​CA Target*
​US Average**
​​​4.1. Data Reporting — RVCT (%)​
99​​99
​98
​98
​98
​—​
​—
​99
​​98**
​4.2 Universal Genotyping (%)
​—
​—
​98
​97
​97
​98
​96
​96*
​​96**

Note: CA Target shown is for latest year of performance, and is marked with * if latest complete year of data meets or exceeds the target.

Note: US Average most current full year of data shown for California; marked with ** if California performance equals or exceeds US performance

Note: California (non-NTIP) indicators shown in italics

Case rates shown are from the National TB Indicators Project (NTIP) reports accessed April 2026, using most current dataset. These rates may differ from those shown in other California-produced reports due to data sources used for population denominators.

Table abbreviations: TB = tuberculosis, US = United States, HIV = human immunodeficiency virus, RVCT = Report of Verified Case of TB, LTBI = latent TB infection, ARPE-CI = Aggregate Report of Performance Evaluation – Contact Investigation, NA = data not available or applicable

California Department of Public Health – Tuberculosis Control Branch                                      updated April 2026​

Page Last Updated :